| BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| BIENAIME JEAN JACQUES | Chief Executive Officer | May 06 | Option Exercise | 37.46 | 20,000 | 749,200 | 355,324 | May 09 09:29 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 06 | Sale | 81.00 | 20,000 | 1,620,000 | 335,324 | May 09 09:29 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 05 | Option Exercise | 37.46 | 10,000 | 374,600 | 345,324 | May 09 09:29 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | May 05 | Sale | 84.14 | 10,000 | 841,400 | 335,324 | May 09 09:29 PM | | Mueller Brian | EVP, Chief Financial Officer | May 04 | Option Exercise | 37.46 | 11,800 | 442,028 | 48,401 | May 06 07:45 PM | | Mueller Brian | EVP, Chief Financial Officer | May 04 | Sale | 84.50 | 11,800 | 997,100 | 38,639 | May 06 07:45 PM | | Davis George Eric | EVP, Chief Legal Officer | May 02 | Option Exercise | 37.46 | 15,347 | 574,899 | 81,686 | May 04 12:01 PM | | MEIER RICHARD A | Director | May 02 | Option Exercise | 37.46 | 8,500 | 318,410 | 107,892 | May 04 12:21 PM | | Davis George Eric | EVP, Chief Legal Officer | May 02 | Sale | 80.38 | 15,347 | 1,233,592 | 66,339 | May 04 12:01 PM | | MEIER RICHARD A | Director | May 02 | Sale | 82.09 | 3,878 | 318,345 | 104,014 | May 04 12:21 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 29 | Option Exercise | 37.46 | 5,000 | 187,300 | 339,983 | May 02 09:27 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 29 | Sale | 81.95 | 5,000 | 409,750 | 334,983 | May 02 09:27 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 28 | Option Exercise | 37.46 | 20,000 | 749,200 | 354,983 | May 02 09:27 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 28 | Sale | 83.79 | 20,000 | 1,675,800 | 334,983 | May 02 09:27 PM | | Davis George Eric | EVP, Chief Legal Officer | Apr 25 | Option Exercise | 37.46 | 2,669 | 99,981 | 65,998 | Apr 27 08:40 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 18 | Option Exercise | 37.46 | 20,000 | 749,200 | 354,983 | Apr 20 08:20 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 18 | Sale | 81.91 | 20,000 | 1,638,200 | 334,983 | Apr 20 08:20 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 14 | Option Exercise | 37.46 | 10,000 | 374,600 | 344,983 | Apr 18 09:46 PM | | LAWLIS V BRYAN | Director | Apr 14 | Option Exercise | 37.46 | 4,250 | 159,205 | 28,220 | Apr 18 08:22 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Apr 14 | Sale | 83.66 | 10,000 | 836,600 | 334,983 | Apr 18 09:46 PM | | LAWLIS V BRYAN | Director | Apr 14 | Sale | 83.66 | 4,250 | 355,555 | 23,970 | Apr 18 08:22 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Apr 13 | Sale | 82.47 | 1,180 | 97,315 | 55,077 | Apr 14 07:54 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Mar 30 | Sale | 79.56 | 1,381 | 109,872 | 56,257 | Mar 31 09:28 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Mar 29 | Sale | 79.43 | 1,618 | 128,518 | 57,638 | Mar 31 09:28 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Mar 23 | Sale | 81.78 | 6,129 | 501,230 | 59,256 | Mar 24 08:49 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Mar 22 | Sale | 81.00 | 2,073 | 167,913 | 65,385 | Mar 24 08:49 PM | | Davis George Eric | EVP, General Counsel | Mar 21 | Sale | 81.29 | 6,129 | 498,226 | 63,329 | Mar 23 09:16 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Mar 11 | Option Exercise | 37.46 | 15,000 | 561,900 | 353,569 | Mar 14 08:44 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Mar 11 | Sale | 77.81 | 15,000 | 1,167,150 | 338,569 | Mar 14 08:44 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Mar 10 | Option Exercise | 37.46 | 15,000 | 561,900 | 353,569 | Mar 14 08:44 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Mar 10 | Sale | 77.57 | 15,000 | 1,163,550 | 338,569 | Mar 14 08:44 PM | | Slamon Dennis | Director | Feb 28 | Sale | 78.33 | 6,396 | 501,013 | 21,639 | Mar 02 04:57 PM | | HERON ELAINE J | Director | Feb 25 | Option Exercise | 37.46 | 8,500 | 318,410 | 80,588 | Feb 28 09:52 PM | | LAWLIS V BRYAN | Director | Jan 14 | Option Exercise | 37.46 | 4,250 | 159,205 | 28,220 | Jan 19 06:34 PM | | LAWLIS V BRYAN | Director | Jan 14 | Sale | 87.61 | 4,250 | 372,342 | 23,970 | Jan 19 06:34 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 13 | Option Exercise | 37.46 | 5,000 | 187,300 | 308,789 | Jan 14 08:45 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 13 | Sale | 87.86 | 5,000 | 439,300 | 303,789 | Jan 14 08:45 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 12 | Option Exercise | 37.46 | 5,000 | 187,300 | 308,789 | Jan 14 08:45 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jan 12 | Sale | 89.00 | 5,000 | 445,000 | 303,789 | Jan 14 08:45 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Dec 16 | Option Exercise | 37.46 | 6,000 | 224,760 | 309,689 | Dec 17 07:03 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Dec 16 | Sale | 84.68 | 6,000 | 508,080 | 303,689 | Dec 17 07:03 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Dec 15 | Option Exercise | 37.46 | 6,000 | 224,760 | 309,689 | Dec 17 07:03 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Dec 15 | Sale | 82.71 | 6,000 | 496,260 | 303,689 | Dec 17 07:03 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Dec 01 | Sale | 87.22 | 1,500 | 130,832 | 304,389 | Dec 02 09:42 PM | | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Oct 26 | Sale | 73.60 | 2,739 | 201,590 | 55,853 | Oct 28 07:48 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Oct 20 | Option Exercise | 37.46 | 1,000 | 37,460 | 305,839 | Oct 22 04:36 PM | | Davis George Eric | EVP, General Counsel | Aug 02 | Sale | 76.69 | 5,518 | 423,175 | 58,590 | Aug 04 04:59 PM | | BIENAIME JEAN JACQUES | Chief Executive Officer | Jun 21 | Option Exercise | 37.46 | 1,000 | 37,460 | 304,839 | Jun 23 05:04 PM |
|
